GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement

GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million

GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025

GenSight Biologics Annual General Meeting on May 13, 2025

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025